title: Soluble histocompatibility antigen class I in breast cancer patients in relation to tumor burden.
abstract: Serum beta-2 microglobulin (B-2M) levels were studied in 365 breast cancer patients and 210 age-matched controls. The patients were divided into three groups: Group A, new patients at diagnosis; Group B, patients at follow-up; and Group C, metastatic patients. The mean B-2M of all breast cancer patients plus or minus one standard deviation (3.5 +/- 1.2; range, 1.1 to 5.9) was significantly higher than normal controls (1.29 +/- 0.49; range, 0.3 to 2.3; P less than 0.005). When the three patient groups were compared with each other, the mean B-2M level of Group A (3.0 +/- 1.5; range, 0.9 to 6.9) was similar to that of Group C (4.22 +/- 1.1; range, 2.0 to 6.4). The mean B-2M of both Groups A and C was significantly higher than that of Group B (2.38 +/- 1.02, range, 0.4 to 5.4; P less than 0.001). In Group A the mean B-2M decreased significantly after a 12-month period and reached the mean level of Group B but not that of normal controls. When patients in Group B were analyzed by their stage of disease at diagnosis, there was no significant difference between Stages I and II. There was a significant difference in the mean B-2M levels between Stages I and III. In relapsing patients, mean B-2M levels increased. These findings suggest that serum B-2M levels may reflect tumor burden, and even in patients at follow-up, occult tumor cells may activate the immune system.
authors.affiliation: Department of Oncology, Beilinson Medical Center, Petah Tiqva, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Klein
authors.forename: T
authors.initials: T
authors.lastname: Klein
authors.forename: A
authors.initials: A
authors.lastname: Figer
authors.forename: M
authors.initials: M
authors.lastname: Bleiberg
authors.forename: J
authors.initials: J
authors.lastname: Shapira
authors.forename: D
authors.initials: D
authors.lastname: Loven
authors.forename: E
authors.initials: E
authors.lastname: Livni
authors.forename: H
authors.initials: H
authors.lastname: Lurie
authors.forename: A
authors.initials: A
authors.lastname: Niska
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D015395:Histocompatibility Antigens Class I / Q000032:analysis*; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000276:immunology; D009367:Neoplasm Staging; D001613:beta 2-Microglobulin / Q000032:analysis
chemical_list: D015395:Histocompatibility Antigens Class I; D001613:beta 2-Microglobulin